Next-Generation First-in-Class Targeted Therapy for Cancer
We identify and stop the key drivers of cancer, autoimmune diseases, and infections
By targeting RAS signalling and translation initiation — two processes that tumours hijack to aid their growth — our therapies cut cancer off at its roots. Our treatment modalities include small molecule inhibitors, antibody-drug conjugates (ADCs), and heterobifunctional degraders.
Zotatifin, our lead asset, is in a Phase 2b clinical trial for various cancer applications. Zotatifin has gained FDA fast-track designation as a triplet combination. Thanks to the unique mechanism of action of our compounds, we can treat many different cancer types, including those that are already resistant.
We are a scientific innovation hub
Health challenges
We address the world’s most devastating cancers and immune disorders with next-generation therapeutics.
Cellular targets
Our focus - RAS and MYC, two of the most challenging molecular targets, for many years considered undruggable.
Drug classes
We expand modalities to match the patient need. By drawing inspiration from nature — like flavaglines — we identify best-in-class drug candidates.
Clinical trials
We translate the most promising preclinical discoveries into safe and effective treatments to patients.